Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) dropped 6.1% during mid-day trading on Wednesday . The company traded as low as $3.20 and last traded at $3.21, with a volume of 298,013 shares traded. The stock had previously closed at $3.42.

ANTH has been the topic of a number of recent analyst reports. Jefferies Group reiterated a “buy” rating on shares of Anthera Pharmaceuticals in a research report on Thursday, June 30th. FBR & Co reiterated a “hold” rating on shares of Anthera Pharmaceuticals in a research report on Monday, June 20th. Zacks Investment Research upgraded Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a research report on Tuesday, April 26th. Finally, HC Wainwright started coverage on Anthera Pharmaceuticals in a research report on Friday, July 8th. They issued a “buy” rating and a $10.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $9.58.

The company’s 50-day moving average price is $3.20 and its 200-day moving average price is $3.41. The stock’s market cap is $142.92 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by $0.04. Equities analysts forecast that Anthera Pharmaceuticals Inc. will post ($1.37) EPS for the current year.

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.